(redirected from Nucynta ER)
Also found in: Dictionary.
Related to Nucynta ER: Tapentadol


(ta-pen-ta-dol) ,


(trade name),

Nucynta ER

(trade name)


Therapeutic: analgesics
Pharmacologic: opioid agonists
Pregnancy Category: C


Management of moderate to severe pain; extended release product should be used for patients requiring around-the-clock management of chronic pain.Diabetic pain associated with diabetic peripheral neuropathy in patients requiring around-the-clock opioid analgesia for an extended time


Acts as μ-opioid receptor agonist.
Also inhibits the reuptake of norepinephrine.

Therapeutic effects

Decrease in pain severity.


Absorption: 32% absorbed following oral administration.
Distribution: Widely distributed.
Metabolism and Excretion: Undergoes extensive first-pass hepatic metabolism (97%); metabolites have no analgesic activity; metabolized drug is 99% renally excreted.
Half-life: 4 hr.

Time/action profile (analgesic effect)

POunknown1 hr4–6 hr


Contraindicated in: HypersensitivitySignificant respiratory depression in unmonitored settings or where resuscitative equipment is not readily available;Paralytic ileus;Severe hepatic or renal impairment;Concurrent MAO inhibitors or use of MAO inhibitors in the preceding 2 wk;Acute or severe bronchial asthma;Acute, mild, intermittent, or postoperative pain (extended-release only); Lactation: Lactation; Pediatric: Safety not established.
Use Cautiously in: Conditions associated with hypoxia, hypercapnea, or ↓ respiratory reserve including asthma, chronic obstructive pulmonary disease, cor pulmonale, extreme obesity, sleep apnea syndrome, myxedema, kyphoscoliosis, CNS depression, use of other CNS depressants or coma (↑ risk of further respiratory depression); use smallest effective dose;History of substance abuse or addiction disorder;Seizure disorders;Moderate hepatic impairment Geriatric: Elderly or debilitated patients (↑ risk of respiratory depression); consider age-related ↓ in hepatic, renal, and cardiovascular function, concurrent disease states and drug therapy (initial dose should be ↓); Obstetric: Use only if potential benefit justifies potential risk to the fetus.

Adverse Reactions/Side Effects

Central nervous system

  • seizures (life-threatening)
  • dizziness
  • headache
  • somnolence


  • respiratory depression (life-threatening)


  • hypotension


  • diarrhea
  • nausea
  • vomiting


  • angioedema (life-threatening)


Drug-Drug interaction

Concurrent MAO inhibitors or use of MAO inhibitors in the preceding 2 wk can result in potentially life-threatening adverse cardiovascular reactions due to additive effects on norepinephrine levels.Concurrent use of other CNS depressants including sedative/hypnotics, alcohol, antihistamines, antidepressants, phenothiazines, and other opioids ↑ risk of further CNS depression; consider dose ↓ of one or both agents.↑ risk of serotonin syndrome with SNRIs, SSRIs, triptans, tricyclic antidepressants, and MAO inihibitors.


When switching from immediate-release to extended-release product, the same total daily dose can be used.
Oral (Adults) Immediate-release or oral solution—50 mg, 75 mg, or 100 mg initially, then every 4–6 hr as needed and tolerated. If pain control is not achieved within first hour of first dose, additional dose may be given. Doses should not exceed 700 mg on the first day or 600 mg/day thereafter; Extended-release—50 twice daily; titrate dose up to 100–250 mg twice daily (not to exceed dose of 500 mg/day).

Hepatic Impairment

Oral (Adults) Moderate hepatic impairment—Immediate release or oral solution: 50 mg every 8 hr initially, then titrate to maintain analgesia without intolerable side effects; Extended-release: 50 mg once daily; may titrate up to maximum dose of 100 mg once daily, if needed.


Immediate-release tablets: 50 mg, 75 mg, 100 mg
Extended-release tablets: 50 mg, 100 mg, 150 mg, 200 mg, 250 mg
Oral solution: 20 mg/mL

Nursing implications

Nursing assessment

  • Assess type, location, and intensity of pain before and 1 hr (peak) after administration.
  • Assess BP and respiratory rate before and periodically during administration. Monitor for respiratory depression especially during initial dosing and with patients at increased risk.
  • Assess bowel function routinely. Prevention of constipation should be instituted with increased intake of fluids and bulk and with laxatives to minimize constipating effects. Administer stimulant laxatives routinely if opioid use exceeds 2–3 days, unless contraindicated.
  • Prolonged use may lead to physical and psychological dependence and tolerance, although these may be milder than with opioids. This should not prevent patient from receiving adequate analgesia. Most patients who receive tapentadol for pain do not develop psychological dependence.
  • Monitor patient for seizures. May occur within recommended dose range. Risk is increased in patients with a history of seizures and in patients taking antidepressants (SSRIs, SNRIs, tricyclics) or other drugs that decrease the seizure threshold.
  • Monitor for serotonin syndrome (mental-status changes [agitation, hallucinations, coma]), autonomic instability [tachycardia, labile BP, hyperthermia], neuromuscular aberrations [hyperreflexia, incoordination] and/or gastrointestinal symptoms [nausea, vomiting, diarrhea] in patients taking SSRIs, SNRIs, triptans, tricyclic antidepressants, or MAO inhibitors concurrently with tapentadol.
  • Overdose may cause respiratory depression. Naloxone (Narcan) may reverse some, but not all, of the symptoms of overdose. Treatment should be symptomatic and supportive. Maintain adequate respiratory exchange.

Potential Nursing Diagnoses

Acute pain (Indications)


  • Initial dose of 50 mg, 75 mg, or 100 mg is individualized based on pain severity, previous experience with similar drugs, and ability to monitor patient. Second dose may be administered as soon as 1 hr after first dose if adequate pain relief is not obtained with first dose.
  • Oral: Tapentadol may be administered without regard to meals.
    • Swallow extended-release tablets whole; do not crush, break or chew.
    • Use calibrated syringe to administer correct dose of oral solution.

Patient/Family Teaching

  • Instruct patient on how and when to ask for and take pain medication and to take tapentadol as directed; do not adjust dose without consulting health care professional. Report breakthrough pain and adverse reactions to health care professional. Do not take tapentadol if pain is mild or can be controlled with other pain medications such as NSAIDs or acetaminophen. Do not stop abruptly; may cause withdrawal symptoms (anxiety, sweating, insomina, rigors, pain, nausea, tremors, diarrhea, upper respiratory symptoms, hallucinations). Decrease dose gradually. Advise patient to read the Medication Guide prior to taking tapentadol and with each Rx refill, in case of new information.
  • Advise patient that tapentadol is a drug with known abuse potential. Protect it from theft, and never give to anyone other than the individual for whom it was prescribed; may be dangerous.
  • May cause dizziness and drowsiness. Caution patient to avoid driving or other activities requiring alertness until response to medication is known.
  • Inform patient that tapentadol may cause seizures. Stop taking tapentadol and notify health care professional immediately if seizures occur.
  • Advise patient to change positions slowly to minimize orthostatic hypotension.
  • Caution patient to avoid concurrent use of alcohol or other CNS depressants with this medication.
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications.
  • Advise patient to notify health care professional if signs of serotonin syndrome occur.
  • Encourage patient to turn, cough, and breathe deeply every 2 hr to prevent atelectasis.
  • Advise female patients to notify health care professional if pregnancy is planned or suspected, or if breast feeding.

Evaluation/Desired Outcomes

  • Decrease in severity of pain without a significant alteration in level of consciousness or respiratory status.
References in periodicals archive ?
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the majority of surveyed primary care physicians (PCPs) and pain specialists indicate that they have experienced reimbursement restrictions when prescribing Janssen's Nucynta ER for chronic low back pain.
Physician & Payer Forum report entitled Chronic Low Back Pain: Reimbursement and Uptake of Novel Agents and Tamper-Resistant Opioids Among Payers and Prescribers also finds that some surveyed MCO pharmacy directors expect the coverage and formulary tier status of Nucynta ER to improve in their largest risk-based commercial plan in one year's time.
Total NUCYNTA ER prescriptions were 80,000 in third quarter, an increase of 8% compared to the second quarter of 2015
NUCYNTA ER weekly prescription volume records set in consecutive weeks in October
NUCYNTA ER year-over-year 4-week rolling prescription volume growth of over 15%
NUCYNTA ER total prescription share in the total LAO market has increased to 1.
NUCYNTA ER prescriptions reached their highest level in almost three years for the week ended September 4, 2015.
NUCYNTA ER prescription growth has accelerated, growing by 15.
We believe that based on this information, Horizon quickly moved to attempt to acquire Depomed before we had the opportunity to (1) re-launch the franchise and (2) announce our record financial results for the second quarter of 2015, our first quarter distributing NUCYNTA and NUCYNTA ER.
Our NUCYNTA franchise includes NUCYNTA ER (tapentadol) extended release tablets, CII indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment, and NUCYNTA (tapentadol) oral tablets, CII, an immediate release version of tapentadol, for management of moderate to severe acute pain in adults.
NUCYNTA ER and Gralise Product Theatre Symposia to Explore Meeting the Unmet Medical Needs of Patients with Pain -